Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

Stock Information for Spero Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Spero Therapeutics Inc.

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Spero Therapeutics Provides Corporate Update and 2024 Outlook
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Spero Therapeutics Inc. (NASDAQ: SPRO)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.